LYMPHOGENiX Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $321K

  • Investors
  • 4

LYMPHOGENiX General Information

Description

Operator of a lymphatic vessel regeneration research company intended to help patients improve their vitality and treatment. The company leverages proprietary technology to revitalize lymphatic function and promote regeneration of various medical conditions to treat heart failure, and pulmonary fibrosis with substantial potential to tackle skin aging, obesity, Alzheimer's disease, and infertility.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 71-75 Shelton Street
  • Covent Garden
  • London WC2H 9JQ
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • 71-75 Shelton Street
  • Covent Garden
  • London WC2H 9JQ
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LYMPHOGENiX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 19-Nov-2024 $321K Completed Startup
To view LYMPHOGENiX’s complete valuation and funding history, request access »

LYMPHOGENiX Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view LYMPHOGENiX’s complete cap table history, request access »

LYMPHOGENiX Patents

LYMPHOGENiX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022344667-A1 Fibroblast-containing pharmaceutical composition for treating kidney disease Pending 08-Sep-2021
EP-4349349-A1 Fibroblast-containing pharmaceutical composition for treating kidney disease Inactive 08-Sep-2021
EP-4349349-A4 Fibroblast-containing pharmaceutical composition for treating kidney disease Inactive 08-Sep-2021
US-20240316113-A1 Fibroblast-containing pharmaceutical composition for treating kidney disease Pending 08-Sep-2021
AU-2022231584-A1 Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same Pending 04-Mar-2021 A61K35/33
To view LYMPHOGENiX’s complete patent history, request access »

LYMPHOGENiX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LYMPHOGENiX Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
AndJ Holdings Venture Capital Minority
Glocalink Venture Capital Minority
Keio Innovation Initiative Venture Capital Minority
S-Quatre Corporation Minority
To view LYMPHOGENiX’s complete investors history, request access »

LYMPHOGENiX FAQs

  • When was LYMPHOGENiX founded?

    LYMPHOGENiX was founded in 2024.

  • Where is LYMPHOGENiX headquartered?

    LYMPHOGENiX is headquartered in London, United Kingdom.

  • What is the size of LYMPHOGENiX?

    LYMPHOGENiX has 3 total employees.

  • What industry is LYMPHOGENiX in?

    LYMPHOGENiX’s primary industry is Biotechnology.

  • Is LYMPHOGENiX a private or public company?

    LYMPHOGENiX is a Private company.

  • What is the current valuation of LYMPHOGENiX?

    The current valuation of LYMPHOGENiX is .

  • What is LYMPHOGENiX’s current revenue?

    The current revenue for LYMPHOGENiX is .

  • How much funding has LYMPHOGENiX raised over time?

    LYMPHOGENiX has raised $321K.

  • Who are LYMPHOGENiX’s investors?

    AndJ Holdings, Glocalink, Keio Innovation Initiative, and S-Quatre have invested in LYMPHOGENiX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process